CANCER PREVENTION RESEARCH

TABLE OF CONTENTS

RESEARCH BRIEF

979 Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer
Deborah L. Burkhart, Katherine L. Morel, Kristine M. Wadosky, David P. Labbé, Phillip M. Galbo, Zafardjan Dalimov, Bo Xu, Massimo Loda, and Leigh Ellis

RESEARCH ARTICLES

989 Blood Supply of Early Lung Adenocarcinomas in Mice and the Tumor-supplying Vessel Relationship: A Micro-CT Angiography Study
Lin Deng, Hanzhou Tang, Jinwei Qiang, Jie Wang, and Shiman Xiao

997 Effect of Antibiotics on Gut and Vaginal Microbiomes Associated with Cervical Cancer Development in Mice
Tatiana V. Karpinets, Travis N. Solley, Megan D. Mikkelson, Stephanie Dorta-Estremera, Sita S. Nookala, Andrea Y. Delgado Medrano, Joseph F. Petrosino, Melissa E. Mezzari, Jinghua Zhang, P. Andrew Futreal, K. Jagannadha Sastry, Lauren E. Colbert, and Ann Klopp

1007 The Association Between Periodontal Disease and Breast Cancer in a Prospective Cohort Study
Mengmeng Jia, Zeni Wu, Emily Vogtmann, Katie M. O’Brien, Clarice R. Weinberg, Dale P. Sandler, and Gretchen L. Gierach

1017 Long-Term Glucocorticoid Use and Cancer Risk: A Population-Based Cohort Study in South Korea
Tak Kyu Oh and In-Ae Song

1027 Characteristics of Breast Ducts in Normal-Risk and High-risk Women and Their Relationship to Ductal Cytologic Atypia
David N. Danforth, Armando C. Filie, Andrew C. Warner, George W. Wright, Zhonghe Sun, Thomas Ried, Christine T. McGowan, and Sheila A. Prindiville

1037 Stakeholder Perspectives on Overcoming Barriers to Cascade Testing in Lynch Syndrome: A Qualitative Study
Swetha Srinivasan, Heather Hampel, Jennifer Leeman, Amit Patel, Alanna Kulchak Rahm, Daniel S. Reuland, and Megan C. Roberts

1047 Upper Endoscopic Surveillance in Lynch Syndrome Detects Gastric and Duodenal Adenocarcinomas
Shria Kumar, Christina M. Dudzik, Mallory Reed, Joseph F. Phelan, Daniel S. Reuland, and Bryson W. Katona

1055 Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial
Justin C. Brown, Sui Zhang, Jennifer A. Ligibel, Melinda L. Irwin, Lee W. Jones, Nancy Campbell, Michael N. Pollak, Alexandra Sorrentino, Brenda Cartmel, Maura Harrigan, Sara M. Tolaney, Eric P. Winer, Kimmie Ng, Thomas A. Abrams, Tara Sanft, Pamela S. Douglas, Frank B. Hu, Charles S. Fuchs, and Jeffrey A. Meyerhardt

AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org
ABOUT THE COVER

Because of its relative latency in disease onset and progression, prostate cancer should be an ideal target for chemoprevention strategies. However, chemoprevention trials for prostate cancer (PCa) by androgen receptor or androgen synthesis inhibition have proven ineffective. It is known that the epigenome becomes corrupted early during PCa initiation, making the epigenome a prime candidate target for PCa prevention. Employing pre-clinical human and mouse models of PCa in a study beginning on page 979, Burkhart and colleagues demonstrate that inhibition of the enhancer of zeste-2 (Ezh2) catalytic activity augmented progression of PCa by induction of tumor cell senescence, raising the overall question regarding Ezh2 inhibition as a potential chemo (epi) prevention strategy for the prevention of prostate cancer. The micrograph on the cover depicts induction of β-galactosidase staining (senescence) following genetic inhibition of Ezh2 catalytic activity in a mouse prostate gland that over-expresses cMYC.